机构:[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine (SJTU-SM), 280 South Chongqing Road, Shanghai 200025, China [2]Department of Pharmacy, Ruijin Hospital, SJTU-SM, 197 Rui Jin Er Road, Shanghai 200025, China [3]Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA [4]Department of Pharmacy, Shanghai University of Medicine & Health Sciences, 279 Zhouzhu Road, Shanghai 201318, China[5]Pathology Center, Shanghai First People's Hospital, SJTU-SM, 280 South Chongqing Road, Shanghai 200025, China [6]Department of General Surgery, Shanghai Tongren Hospital, SJTU-SM, 1111 Xianxia Road, Shanghai 200336, China
Normalization of the tumor microenvironment is a promising approach to render conventional chemotherapy more effective. Although passively targeted drug nanocarriers have been investigated to this end, actively targeted tumor priming remains to be explored. In this work, we demonstrate an effective tumor priming strategy using metronomic application of nanoparticles actively targeted to tumor neovasculature. F56 peptide-conjugated paclitaxel-loaded nanoparticles (F56-PTX-NP) were formulated from PEGylated polylactide using an oil in water emulsion approach. Metronomic F56-PTX-NP specifically targeted tumor vascular endothelial cells (ECs), pruned vessels with strong antiangiogenic activity and induced thrombospondin-1 (TSP-1) secretion from ECs. The treatment induced tumor vasculature normalization as evidenced by significantly increased coverage of basement membrane and pericytes. The tumor microenvironment was altered with enhanced pO(2), lower interstitial fluid pressure, and enhanced vascular perfusion and doxorubicin delivery. A "normalization window" of at least 9 days was induced, which was longer than other approaches using antiangiogenic agents. Together, these results show that metronomic, actively-targeted nanomedicine can induce tumor vascular normalization and modulate the tumor microenvironment, opening a window of opportunity for effective combination chemotherapies. (C) 2016 Elsevier Ltd. All rights reserved.
基金:
National Basic Research Program of ChinaNational Basic Research Program of China [2010CB529806]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81272569, 81572998]; Shanghai Municipal Science and Technology CommissionScience & Technology Commission of Shanghai Municipality (STCSM) [14JC1491900]; Innovation Program of Shanghai Municipal Education CommissionInnovation Program of Shanghai Municipal Education Commission [13ZZ087]
第一作者机构:[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine (SJTU-SM), 280 South Chongqing Road, Shanghai 200025, China [2]Department of Pharmacy, Ruijin Hospital, SJTU-SM, 197 Rui Jin Er Road, Shanghai 200025, China
通讯作者:
通讯机构:[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine (SJTU-SM), 280 South Chongqing Road, Shanghai 200025, China [2]Department of Pharmacy, Ruijin Hospital, SJTU-SM, 197 Rui Jin Er Road, Shanghai 200025, China
推荐引用方式(GB/T 7714):
Luan Xin,Guan Ying-Yun,Lovell Jonathan F.,et al.Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel[J].BIOMATERIALS.2016,95:60-73.doi:10.1016/j.biomaterials.2016.04.008.
APA:
Luan, Xin,Guan, Ying-Yun,Lovell, Jonathan F.,Zhao, Mei,Lu, Qin...&Chen, Hong-Zhuan.(2016).Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel.BIOMATERIALS,95,
MLA:
Luan, Xin,et al."Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel".BIOMATERIALS 95.(2016):60-73